Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.3 USD | -1.69% | +2.45% | -9.97% |
May. 10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.97% | 1.43B | |
+31.37% | 588B | |
-2.83% | 364B | |
+20.55% | 326B | |
+5.47% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.97% | 167B | |
+0.21% | 161B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating